AllSight
Companies · ZTS · Pharmaceutical Preparations

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Zoetis Inc. (ZTS) stock — financials & valuation

Key numbers for Zoetis Inc. (ZTS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 63/100 — a percentile rank of Zoetis Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$28.9B
P / E11.0×
P / S3.0×
EV / EBITDA9.0×
Gross margin71.5%
Operating margin36.4%
Net margin27.5%
Return on equity83.1%
ROIC25.8%
Revenue growth1.5%
Debt / equity2.9×
Dividend yield3.1%

Is Zoetis Inc. overvalued? P/E looks undervalued vs its 5-year range; P/S looks undervalued vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks undervalued vs its 5-year range.

Independent of the events above — derived from Zoetis Inc.’s own financial statements and shown as context, never as advice.

Aug 6, 2026
Guidance slashed as U.S. pet weakness overwhelms a near-consensus quarter
Aug 6, 2026
Zoetis names a combined CFO-COO, replacing Joseph in an orderly transition
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact